Quinoline-based antifungals.

Although the assortment of antifungal drugs is broad, the most commonly used agents have major drawbacks. Toxicity, serious side effects or the emergence of drug resistance are amongst them. New drugs and drug candidates under clinical trials do not guarantee better pharmacological parameters. These new medicines may appear effective; however; they may cause serious side effects. This current review is focused on the recent findings in the design of quinoline based antifungal agents. This field seems to be especially interesting as 8-hydroxyquinoline and its metal complexes have been well known as antifungals for years. Structural similarities between quinoline based antifungals and allylamines or homoallylamines, e.g. terbinafine is another interesting fact. Quinoline can be identified in a number of synthetic and natural antifungals, which indicates nature's preference for this fragment and identifying it as one of the so-called privileged structures. We have discussed new trends in the design of quinolines with antifungal properties, their possible targets and the structure activity relationships within the antifungal series developed.

[1]  J. Polanski,et al.  An Efficient Microwave-Assisted Synthesis of Structurally Diverse Styrylquinolines , 2006 .

[2]  J. D. Wansi,et al.  Alkaloids from Oriciopsis glaberrima Engl. (Rutaceae). , 2006, Phytochemistry.

[3]  H. Tabuchi,et al.  Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis , 1997, Journal of bacteriology.

[4]  R. Abraham,et al.  Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. , 2003, Molecular cancer therapeutics.

[5]  D. R. Clifford,et al.  Fungicidal activity and chemical constitution , 1969 .

[6]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[7]  G. Fadda,et al.  Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance , 2005, Antimicrobial Agents and Chemotherapy.

[8]  R. Enriz,et al.  Structure-activity relationship study of homoallylamines and related derivatives acting as antifungal agents. , 2006, Bioorganic & medicinal chemistry.

[9]  J. Polanski,et al.  Ring-substituted 4-Hydroxy-1H-quinolin-2-ones: Preparation and Biological Activity , 2009, Molecules.

[10]  P. Hirsova,et al.  Rhodanineacetic Acid Derivatives as Potential Drugs: Preparation, Hydrophobic Properties and Antifungal Activity of (5-Arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)acetic Acids † , 2009, Molecules.

[11]  E. Mylonakis,et al.  New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. Tekwani,et al.  Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues. , 2005, Bioorganic & medicinal chemistry.

[13]  M. Taniguchi,et al.  Semi-synthesis and biological evaluation of analogues of UK-2A, a novel antifungal antibiotic from Streptomyces sp. 517-02. , 2005, Bioorganic & medicinal chemistry letters.

[14]  A. Albert,et al.  The influence of chemical constitution on antibacterial activity. VI. The bactericidal action of 8-hydroxyquinoline (oxine). , 1953, British journal of experimental pathology.

[15]  V. Yu,et al.  Experiences of the first 16 hospitals using copper-silver ionization for Legionella control: implications for the evaluation of other disinfection modalities. , 2003, Infection control and hospital epidemiology.

[16]  L. Kuyper,et al.  X-ray Crystallographic Studies of Candida albicans Dihydrofolate Reductase , 1997, The Journal of Biological Chemistry.

[17]  D. Warnock Trends in the epidemiology of invasive fungal infections. , 2007, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.

[18]  G. Nicoletti,et al.  Fungitoxicity of oxine and copper oxinate : activity spectrum, development of resistance and synergy , 1999 .

[19]  K. Bastow,et al.  Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone. , 1999, Biochemical pharmacology.

[20]  S. J. Holt,et al.  111. Carbazoles, carbolines, and related compounds. Part I. Quindoline derivatives , 1947 .

[21]  E. Anaissie,et al.  Nosocomial fungal infections. Old problems and new challenges. , 1989, Infectious disease clinics of North America.

[22]  O. Yarden,et al.  Protein phosphatase 2A is involved in hyphal growth of Neurospora crassa , 1998, Molecular and General Genetics MGG.

[23]  S. Block Chelate Fungicides, Fungitoxicity of 8-Quinolinols , 1955 .

[24]  D. Boger,et al.  Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones. , 1987, Journal of medicinal chemistry.

[25]  M. Weinstock,et al.  Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. , 1999, American journal of public health.

[26]  A. Albert,et al.  The influence of chemical constitution of antibacterial activity; a study of 8-hydroxyquinolin (oxine) and related compounds. , 1947 .

[27]  R. Enriz,et al.  Inhibitors of the fungal cell wall. Synthesis of 4-aryl-4-N-arylamine-1-butenes and related compounds with inhibitory activities on beta(1-3) glucan and chitin synthases. , 2000, Bioorganic & medicinal chemistry.

[28]  J. Simons,et al.  Cell wall 1,6‐β‐glucan synthesis in Saccharomyces cerevisiae depends on ER glucosidases I and II, and the molecular chaperone BiP/Kar2p , 1998, The EMBO journal.

[29]  C. Payá,et al.  Fusarium infection after solid-organ transplantation. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Michael Quinoline, quinazoline and acridone alkaloids. , 2001, Natural product reports.

[31]  Vithal M. Kulkarni,et al.  Design, synthesis, antifungal activity, and ADME prediction of functional analogues of terbinafine , 2009, Medicinal Chemistry Research.

[32]  J. Fostel,et al.  Emerging novel antifungal agents. , 2000, Drug discovery today.

[33]  Matthew R. Redinbo,et al.  New potential targets for antifungal development , 2000 .

[34]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[35]  S. Ablordeppey,et al.  Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development. , 1999, Current medicinal chemistry.

[36]  M. Schaller,et al.  Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. , 2001, International journal of antimicrobial agents.

[37]  D. Taramelli,et al.  Inhibition of Intramacrophage Growth ofPenicillium marneffei by 4-Aminoquinolines , 2001, Antimicrobial Agents and Chemotherapy.

[38]  D. Andes,et al.  Pharmacology of Systemic Antifungal Agents , 2006 .

[39]  J. Polanski,et al.  Antifungal properties of new series of quinoline derivatives. , 2006, Bioorganic & medicinal chemistry.

[40]  R. Enriz,et al.  In vitro antifungal evaluation and structure-activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. , 2001, Bioorganic & medicinal chemistry.

[41]  S. Zanetti,et al.  Novel functionalized pyrido[2,3-g]quinoxalinones as antibacterial, antifungal and anticancer agents. , 2001, Farmaco.

[42]  M. Hassar,et al.  Antileishmanial activity of a new 8-hydroxyquinoline derivative designed 7-[5'-(3'-phenylisoxazolino)methyl]-8-hydroxyquinoline: preliminary study. , 2004, Farmaco.

[43]  K. Schrader,et al.  Isolation and identification of antifungal and antialgal alkaloids from Haplophyllum sieversii. , 2005, Journal of agricultural and food chemistry.

[44]  T. Doyle,et al.  Isolation of lavendamycin, a new antibiotic from Streptomyces lavendulae. , 1982, The Journal of antibiotics.

[45]  J. Daly,et al.  Alkaloids of Anuran Skin: Antimicrobial Function? , 2005, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[46]  R. Chen,et al.  Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs , 1997, Antimicrobial agents and chemotherapy.

[47]  R. Esposito,et al.  The relationship of pteridine biosynthesis to the action of copper 8-hydroxyquinolate on fungal spores. , 1961, Archives of biochemistry and biophysics.

[48]  J. Wandji,et al.  α-Glucosidase Inhibitory and Antioxidant Acridone Alkaloids from the Stem Bark of Oriciopsis glaberrima E NGL . (Rutaceae) , 2006 .

[49]  B. Plikaytis,et al.  Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  K. Goa,et al.  Terbinafine , 2003, American journal of clinical dermatology.

[51]  P. Gershkovich,et al.  Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. , 2009, The Journal of infectious diseases.

[52]  C. Ryu,et al.  The synthesis of 6-(N-Arylamino)-7-chloro-5,8-quinolinedione derivatives for evaluation of antifungal activities , 1994 .

[53]  D. Clarke,et al.  Evidence of steric factors in the fungitoxic mechanisms of 8-quinolinol and its 5- and 7-halogenated analogues. , 1991, Journal of pharmaceutical sciences.

[54]  R. Nandhakumar,et al.  Synthesis, antimicrobial activities and cytogenetic studies of newer diazepino quinoline derivatives via Vilsmeier-Haack reaction. , 2007, European journal of medicinal chemistry.

[55]  John J McGuire,et al.  Anticancer antifolates: current status and future directions. , 2003, Current pharmaceutical design.

[56]  C. Wright Recent developments in naturally derived antimalarials: cryptolepine analogues , 2007, The Journal of pharmacy and pharmacology.

[57]  G. Gustafson,et al.  Identification of a new antifungal target site through a dual biochemical and molecular-genetics approach , 1996, Current Genetics.

[58]  R. Enriz,et al.  In vitro antifungal activity of new series of homoallylamines and related compounds with inhibitory properties of the synthesis of fungal cell wall polymers. , 2003, Bioorganic & medicinal chemistry.

[59]  L. Wessjohann,et al.  (Iso)-quinoline alkaloids from fungal fruiting bodies of Cortinarius subtortus. , 2008, Journal of natural products.

[60]  Gerard D. Wright,et al.  Simultaneous in vitro assay of the first four enzymes in the fungal aspartate pathway identifies a new class of aspartate kinase inhibitor. , 2003, Chemistry & biology.

[61]  Jain,et al.  Occurrence and significance of decahydroquinolines from dendrobatid poison frogs and a myrmicine ant: use of 1H and 13C NMR in their conformational analysis , 1999, Journal of natural products.

[62]  V. Buchta,et al.  Quinaldine derivatives: preparation and biological activity. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[63]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  H. Gershon,et al.  Antifungal Activity of 5-, 7-, and 5,7-Substituted 2-Methyl-8-Quinolinols , 1972, Antimicrobial Agents and Chemotherapy.

[65]  S. Zacchino,et al.  In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions. , 2008, Bioorganic & medicinal chemistry.

[66]  W. Dismukes Antifungal therapy: lessons learned over the past 27 years. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[68]  T. C. White,et al.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[69]  J. Sturtevant Translation elongation-3-like factors: are they rational antifungal targets? , 2002, Expert opinion on therapeutic targets.

[70]  C. Kunin,et al.  Antimicrobial Activities of Mefloquine and a Series of Related Compounds , 2000, Antimicrobial Agents and Chemotherapy.

[71]  J. Polanski,et al.  RP-HPLC determination of lipophilicity in series of quinoline derivatives , 2009 .

[72]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[73]  D. Anderson Sitafloxacin hydrate for bacterial infections. , 2008, Drugs of today.

[74]  V L Yu,et al.  Copper-silver ionization: cautious optimism for Legionella disinfection and implications for environmental culturing. , 1997, American journal of infection control.

[75]  H. Bhojya Naik,et al.  Transition Metal Complexes of Quinolino[3,2-b]benzodiazepine and Quinolino[3,2-b]benzoxazepine: Synthesis, Characterization, and Antimicrobial Studies , 2007, Bioinorganic chemistry and applications.

[76]  H. Gershon,et al.  Secondary mechanisms of antifungal action of substituted 8-quinolinols. 3. 5,7,8-Substituted quinolines. , 1972, Journal of medicinal chemistry.

[77]  N. Ryder,et al.  Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.

[78]  D. Stevens,et al.  Efficacy of nikkomycin Z against experimental pulmonary blastomycosis , 1997, Antimicrobial agents and chemotherapy.

[79]  J. Polanski,et al.  Investigating Biological Activity Spectrum for Novel Styrylquinazoline Analogues , 2009, Molecules.

[80]  K. Valko,et al.  Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. , 2004, Journal of chromatography. A.

[81]  T. Harrison,et al.  Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. , 1997, The Journal of clinical investigation.

[82]  U. Murthy,et al.  Synthesis of multisubstituted quinolines from Baylis-Hillman adducts obtained from substituted 2-chloronicotinaldehydes and their antimicrobial activity. , 2006, Bioorganic & medicinal chemistry.

[83]  D. Clarke,et al.  Antifungal activity of substituted 8-quinolinol-5- and 7-sulfonic acids: a mechanism of action is suggested based on intramolecular synergism , 2004, Mycopathologia.

[84]  E. Chahine,et al.  Echinocandins: The Newest Class of Antifungals , 2009, The Annals of pharmacotherapy.

[85]  T. Walsh,et al.  Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal Agents and Ciprofloxacin against Candida albicans and Aspergillus fumigatus , 2008, Antimicrobial Agents and Chemotherapy.

[86]  H. Gershon,et al.  Intramolecular synergism, an explanation for the enhanced fungitoxicity of halo-8-quinolinols , 1995 .

[87]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[88]  O. Bueno,et al.  A New Imidazole Alkaloid and Other Constituents from Pilocarpus grandiflorus and their Antifungal Activity , 2005 .

[89]  S. Ignacimuthu,et al.  Antibacterial and antifungal activity of Flindersine isolated from the traditional medicinal plant, Toddalia asiatica (L.) Lam. , 2009, Journal of ethnopharmacology.

[90]  C. Kauffman Zygomycosis: reemergence of an old pathogen. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  E. Anaissie,et al.  Fusarium infection in hematopoietic stem cell transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[92]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[93]  K. Metwally,et al.  Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents. , 2006, Bioorganic & medicinal chemistry.

[94]  M. Ypma-Wong,et al.  Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii , 1992, Infection and immunity.

[95]  N. Gow,et al.  Antifungal agents: mechanisms of action. , 2003, Trends in microbiology.

[96]  K. Marr,et al.  Emerging fungal diseases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  Federico Corelli,et al.  The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. , 2009, Current medicinal chemistry.

[98]  M. Tanaka,et al.  In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi , 1995, Antimicrobial agents and chemotherapy.

[99]  B. Hube,et al.  The role of secreted aspartyl proteinases in Candida albicans keratitis. , 2007, Investigative ophthalmology & visual science.

[100]  N. Ryder,et al.  Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents , 1996, Antimicrobial agents and chemotherapy.

[101]  S. Geller,et al.  Terbinafine Hepatotoxicity: Case Report and Review of the Literature , 1998, American Journal of Gastroenterology.

[102]  G. Deepe,et al.  Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. , 1994, The Journal of clinical investigation.

[103]  A. Mascarello,et al.  Relation between lipophilicity of alkyl gallates and antifungal activity against yeasts and filamentous fungi. , 2009, Bioorganic & medicinal chemistry letters.

[104]  S. Ablordeppey,et al.  Indolo[3,2-b]quinolines: synthesis, biological evaluation and structure activity-relationships. , 2008, Mini reviews in medicinal chemistry.

[105]  Jeffrey P. Jones,et al.  Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues. , 2008, Journal of medicinal chemistry.

[106]  L. Kuyper,et al.  Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines. , 1995, Journal of medicinal chemistry.